ReviewOxidative medicine and cellular longevity2020
Molecular Insight into the Therapeutic Promise of Targeting
Review in Oxidative medicine and cellular longevity, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 54 citations in OpenAlex.
- Pivotal trial of low-intensity pulsed ultrasound therapy for early Alzheimer's disease: Rationale and design.Journal of Alzheimer's disease reportsTrial
- Cortical layer multi-parameter analysis of neurovascular impairments in AD/ADRD rodent model with in vivo optical imaging.Translational neurodegeneration · 2025Article
- Non-Drug and Non-Invasive Therapeutic Options in Alzheimer's Disease.Biomedicines · 2025Review
- Multiple Roles of Apolipoprotein E4 in Oxidative Lipid Metabolism and Ferroptosis During the Pathogenesis of Alzheimer's Disease.Journal of molecular neuroscience : MN · 2024Review
- Brain organoids: A revolutionary tool for modeling neurological disorders and development of therapeutics.Biotechnology and bioengineering · 2024Review
- Effect of thymol on oxidative stress and reelin signaling pathway in Alzheimer's disease model.Turkish journal of biology = Turk biyoloji dergisi · 2024Article
- Article
- Lipid Metabolic Disorders in Neurodegenerative Diseases - Role of Androgen Receptor.The Eurasian journal of medicine · 2023Review
- Current progress of cerebral organoids for modeling Alzheimer's disease origins and mechanisms.Bioengineering & translational medicine · 2023Review
- An increase in mitochondrial TOM activates apoptosis to drive retinal neurodegeneration.Scientific reports · 2022Article
- Astrocytes as a Therapeutic Target in Alzheimer's Disease-Comprehensive Review and Recent Developments.International journal of molecular sciences · 2022Review
- Alzheimer's Disease and SARS-CoV-2: Pathophysiological Analysis and Social Context.Brain sciences · 2022Review
- Fully automated and highly specific plasma β-amyloid immunoassays predict β-amyloid status defined by amyloid positron emission tomography with high accuracy.Alzheimer's research & therapy · 2022Article
- Mediation of the APOE associations with Alzheimer's and coronary heart diseases through body mass index and lipids.GeroScience · 2022Article
- Diagnostic Accuracy of Blood-Based Biomarker Panels: A Systematic Review.Frontiers in aging neuroscience · 2022Article
- Genetic variant rs11136000 upregulates clusterin expression and reduces Alzheimer's disease risk.Frontiers in neuroscience · 2022Article
- Role of Phenolic Compounds in Human Disease: Current Knowledge and Future Prospects.Molecules (Basel, Switzerland) · 2021Review
- Exploring the Role of CLU in the Pathogenesis of Alzheimer's Disease.Neurotoxicity research · 2021Review
- Exercise as Potential Therapeutic Target to Modulate Alzheimer's Disease Pathology in APOE ε4 Carriers: A Systematic Review.Cardiology and therapy · 2021Review
- Genetic Counselling Improves the Molecular Characterisation of Dementing Disorders.Journal of personalized medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 9 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is a progressive neurodegenerative disease that causes chronic cognitive dysfunction. Most of the AD cases are late onset, and the apolipoprotein E (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.